drugset

drugset / Trial / NCT00205920

Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

NCT00205920 ↗

Phase 2 Terminated 5 enrolled Aeris Therapeutics

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effective dose of the Aeris BLVR System in patients with advanced emphysema.

Timeline

Start: 2005-05
Primary completion: 2006-09
Completion: 2007-05

Outcome

Outcome not reported

Stopped: “Change in formulation”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BLVR Hydrogel	Unknown	10 ml	Other

Indications